Scandion Oncology (Scandion) strengthens its Executive Management with the inclusion of Jan Stenvang, who is appointed Chief Scientific Officer (CSO) reporting directly to CEO Francois Martelet. A co-founder of Scandion, Jan Stenvang led the initial research and discoveries upon which Scandion is based. He has headed the company's research and early development activities ever since and has played a pivotal role in e.g. the planning and execution of the development of Scandion's lead compound SCO-101.

In his new role he will continue this work, also focusing on potential new indications that Scandion could pursue. With a master's degree and Ph.D. in Molecular and Cellular Biology, Jan Stenvang has specialized in translational cancer research particularly focusing on drug resistance and biomarker identification. Before co-founding Scandion, he spent most of his career in academia as e.g. Group Leader and Associate Professor at Copenhagen University and also as Group Leader at the biotech company Santaris Pharma.

Combined, Jan Stenvang has more than 20 years of experience in cancer research.